Waystar (NASDAQ: WAY) jumps 7% on sale report as 43% EBITDA margin attracts attention

Waystar Holding Corp. (NASDAQ: WAY), a healthcare-payment software company whose technology helps hospitals and healthcare providers manage billing and revenue-cycle processes, jumped 7.1% to $26.67 on September 15 after Reuters reported that the company is exploring strategic alternatives including a potential sale. Waystar has reportedly engaged Evercore and Barclays to advise on the early-stage process, although no final decision has been made.

The reaction lifted Waystar’s market capitalisation to roughly $5.1 billion and created an unusual setup for a company that listed in 2024. Investors now need to assess both the standalone value of a software platform producing 18% revenue growth and a 43% adjusted EBITDA margin and the possibility that a strategic or financial buyer may be willing to pay a control premium.

Why might Waystar become an acquisition target only two years after going public?

Waystar occupies a strategically attractive position between healthcare providers, insurers and patients. Its software automates administrative and payment processes that are complicated, expensive and deeply embedded in healthcare operations.

Healthcare organisations have powerful incentives to reduce claim denials, shorten collection cycles and automate repetitive revenue-cycle tasks. Software that can demonstrate measurable financial improvement can therefore become difficult for customers to remove once integrated into workflows.

Waystar’s latest financial metrics strengthen the potential takeover logic. Q2 revenue increased 18% to $319.7 million, adjusted EBITDA reached $136.7 million and the adjusted EBITDA margin was approximately 43%.

A company combining high-teens growth with margins above 40% is economically attractive because it offers both expansion and substantial present profitability. That combination is unusual enough to draw attention from private-equity firms or larger technology and healthcare-services groups.

How much of Waystar’s growth is coming from recurring subscription revenue?

Subscription revenue increased 34% year over year to $176.3 million in Q2, substantially faster than overall revenue. Volume-based revenue increased only 3% to $142.1 million, meaning subscriptions are gradually becoming a more important driver of growth.

That mix matters because subscription revenue tends to provide greater visibility and can support higher valuation multiples than transaction activity that fluctuates directly with processing volumes.

Waystar reported 1,453 customers contributing more than $100,000 each in trailing-12-month revenue, up 15% year over year, while net revenue retention stood at 108%. Those figures indicate that large-client relationships are expanding even after accounting for customer losses and contractions.

The company is consequently not entering a strategic review from a position of obvious operating distress. That raises the prospect that any sale discussion could revolve around maximising value rather than repairing a broken business.

Does artificial intelligence make Waystar more valuable or more vulnerable?

Artificial intelligence is one reason healthcare software valuations have become more complicated. Investors worry that new AI tools could automate tasks previously requiring specialised software, compressing the value of incumbent platforms.

Waystar argues that AI can instead strengthen its offering because it possesses healthcare-domain data, established integrations and access to payment workflows. Its AltitudeAI tools are being embedded into existing products rather than developed as an entirely separate business.

The key distinction is whether AI replaces software vendors or makes vendors with strong datasets and distribution more productive. A buyer evaluating Waystar would likely focus heavily on the durability of its data advantage, customer integrations and ability to automate additional revenue-cycle functions.

The 43% adjusted EBITDA margin provides a cushion while that debate develops. Waystar is funding AI development from a highly profitable operating model rather than relying on continuous external capital.

What does the $26.67 share price imply after the takeover report?

Waystar closed at $26.67 on September 15 after gaining 7.1%, following another 6.1% gain the preceding day. Market capitalisation reached roughly $5.11 billion.

The stock therefore already contains some strategic-premium speculation. A potential buyer would normally need to offer enough above the unaffected price to win shareholder approval, but there is currently no disclosed offer and no certainty that Waystar will ultimately sell itself.

This makes the stock event-driven in the near term. If credible bidders emerge, investors may begin benchmarking possible prices against growth, EBITDA and comparable healthcare-software transactions.

If the process ends without a transaction, the takeover premium can disappear and the valuation will return to Waystar’s standalone financial outlook.

How strong is the standalone case if no sale occurs?

Waystar raised its 2026 outlook in July and expects revenue of approximately $1.276 billion to $1.294 billion. Adjusted EBITDA is projected at $535 million to $545 million, while non-GAAP net income is expected between $322 million and $340 million.

At the midpoints, that implies roughly $1.285 billion of revenue and $540 million of adjusted EBITDA, corresponding to an adjusted EBITDA margin around 42%.

That combination makes Waystar fundamentally different from software businesses whose takeover appeal rests mostly on cutting costs. The company already operates with substantial profitability, so a buyer would need to identify additional value from growth, cross-selling, leverage, product expansion or strategic integration.

The strongest roadmap conclusion is therefore that Waystar does not require a takeover for the operating story to work. The potential sale simply introduces another route through which shareholders might realise value sooner.